Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico
- Adrián Martínez-Meléndez,
- ,
- Rayo Morfin-Otero,
- Adrián Camacho-Ortíz,
- Licet Villarreal-Treviño,
- Hugo Sánchez-Alanís
- Universidad Autonoma de Nuevo Leon,
- Department of Microbiology and Immunology,
- Universidad de Guadalajara,
- University of Hertfordshire
Publication metrics
Metrics
Abstract
OBJECTIVE: To assess drug susceptibility and characterize Clostridium difficile ribotypes in isolates from two tertiary-care hospitals in Mexico.
METHODS: Isolates were evaluated for genotyping, antimicrobial susceptibility testing and detection of mutations associated with drug resistance. PCR ribotyping was performed using a combination of gel-based and capillary electrophoresis-based approaches.
RESULTS: MIC50 and MIC90 were ≥128 mg/L for ciprofloxacin, erythromycin, clindamycin, and rifampicin. There was no reduced susceptibility to metronidazole or tetracycline; however, reduced susceptibility to vancomycin (≥4 mg/L) and fidaxomicin (≥2 mg/L) was detected in 50 (40.3%) and 4 (3.2%) isolates, respectively. Furthermore, the rpoB Arg505Lys mutation was more frequently detected in isolates with high minimum inhibitory concentration (MIC) to rifampicin (≥32 mg/L) (OR = 52.5; 95% CI = 5.17-532.6; p < 0.000). Of the 124 C. difficile isolates recovered, 84 (66.7%) were of ribotype 027, 18 (14.5%) of ribotype 001, and the remainder were other ribotypes (353, 255, 220, 208, 176, 106, 076, 020, 019, 017, 014, 012, 003, and 002).
CONCLUSION: Ribotypes 027 and 001 were the most frequent C. difficile isolates recovered in this study, and demonstrated higher MICs. Furthermore, we found four isolates with reduced susceptibility to fidaxomicin, raising a concern since this drug is currently unavailable in Mexican Hospitals.
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 386-392 (7 pages)Journal (Volume, Issue Number)
Microbial Drug Resistance (Volume 24, Issue 4)Publication milestones
- Published - 01/05/2018
Publication status
ISSN
1076-6294Publication IDs
- Scopus: 85054460749
- PubMed: 29485939
